NEU 2.37% $19.39 neuren pharmaceuticals limited

biggest competitor to nnz-2566

  1. 1,516 Posts.
    lightbulb Created with Sketch. 1899
    We understand the similarities between NNZ-2566 and NNZ-2591 but it is understanding the differences which will create alternative therapeutic pathways. It appears that NNZ-2591 may have a more direct effect on synaptic signalling.

    Neurons do not connect with each other but communicate through a junction called a synapse. The junction is what Professor Mike Snape - http://vimeo.com/71532531 - might call the 'twitter space' where there are glia-neuron interactions, namely microglia and astrocyte.

    There is a growing level of excitement about the MOA for NNZ-2591. The US Army is "characterising the impact of the drug on the restoration of synaptic function". Neuren have commenced testing NNZ-2591 in a mouse model of MS which is characterised in part by abnormal functioning of microglia.

    Although the reasons are not yet fully understood, it does appear that NNZ-2591 is quite distinct from NNZ-2566. The results from the testing of NNZ-2591 in a mouse model for MS are eagerly anticipated.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$19.39
Change
-0.470(2.37%)
Mkt cap ! $2.478B
Open High Low Value Volume
$19.70 $19.77 $19.28 $10.38M 534.0K

Buyers (Bids)

No. Vol. Price($)
3 2680 $19.35
 

Sellers (Offers)

Price($) Vol. No.
$19.41 362 1
View Market Depth
Last trade - 16.10pm 30/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.